An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

(2018) Michele Caruso et al.   CANCER RESEARCH

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

(2017) Yael P. Mossé et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

(2017) Alec J. Walker et al.   MOLECULAR THERAPY

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

(2016) Lori S. Hart et al.   CLINICAL CANCER RESEARCH

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

(2016) Andrew C. Wood et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis

(2016) Valentina E. Schneeberger et al.   PLoS One

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

(2015) Kristopher R. Bosse et al.   CANCER

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies

(2015) Y. P. Mosse   CLINICAL CANCER RESEARCH

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

(2015) K. Krytska et al.   CLINICAL CANCER RESEARCH

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions

(2015) Andrey V. Reshetnyak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

(2015) N. R. Infarinato et al.   Cancer Discovery

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

(2015) Jikui Guan et al.   eLife

Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)

(2015) Barbara Valsasina et al.   CANCER RESEARCH

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part III - analytical issues

(2013) Shabnam Tanqri et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

(2012) E L Carpenter et al.   ONCOGENE

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

(2011) S. C. Bresler et al.   Science Translational Medicine

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE